Scrip's Guide To Spinal Muscular Atrophy Therapies
INFOGRAPHIC: The prospects for patients with spinal muscular atrophy, the leading cause of genetic death in infants, have been revolutionized by the arrival of the first approved drug for the disease, Biogen’s blockbuster Spinraza. Now, other firms with equally revolutionary product candidates are giving chase. Scrip takes a look at the main contenders.
You may also be interested in...
Novartis and Roche have announced additional interim clinical data as their candidate spinal muscular atrophy therapies near the marketplace.
The Russian ministry of health has raised eyebrows by approving a vaccine against SARS-CoV-2 just weeks after its first clinical trials in 76 volunteers. Phase III confirmatory studies await for the adenovirus-based product but a mass vaccination plan is slated to begin in October.
A first look at the clinical data for Novavax’s COVID-19 vaccine suggests it can produce strong antibody responses while being well tolerated.